|
|
Volumn 7, Issue 11, 2008, Pages 880-881
|
|
Trial watch: novel biologic for psoriasis shows superiority over current best-seller.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CNTO 1275;
IMMUNOGLOBULIN G;
INTERLEUKIN 12;
INTERLEUKIN 23;
MONOCLONAL ANTIBODY;
TNFR FC FUSION PROTEIN;
TNFR-FC FUSION PROTEIN;
TUMOR NECROSIS FACTOR RECEPTOR;
DRUG ADMINISTRATION;
DRUG ANTAGONISM;
HOSPITALIZATION;
HUMAN;
IMMUNOLOGY;
NOTE;
PHASE 3 CLINICAL TRIAL;
PSORIASIS;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG ADMINISTRATION SCHEDULE;
HUMANS;
IMMUNOGLOBULIN G;
INTERLEUKIN-12;
INTERLEUKIN-23;
PSORIASIS;
RECEPTORS, TUMOR NECROSIS FACTOR;
SEVERITY OF ILLNESS INDEX;
|
|
EID: 56049084440
PISSN: None
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2753 Document Type: Note |
|
Times cited : (10)
|
|
References (0)
|